hc1, a leader in transforming lab data into actionable intelligence that improves patient health outcomes while boosting the bottom line, announced it raised $6.25 million in new financing after a successful acquisition in October 2024 of Accumen. Existing investor Health Cloud Capital led the investment with participation from health tech investment firm A1 Health Ventures. And Arsenal Capital Partners joined the investor base in the combined platform via its ownership stake in Accumen.
This funding round will support the launching of enhanced solutions that couple hc1 + Accumen’s market-leading technology and expertise. And this strategic growth initiative advances hc1’s goal of driving healthcare progress through predictive insights, personalized care, and increased efficiencies.
Patients are frequently over- or under-tested and diagnosed with limited and point-in-time diagnostic snapshots that fail to capture the complete picture of their health. This leads to delayed diagnoses, waste in unreimbursed testing, missed opportunities to predict patient health conditions and adverse patient outcomes.
The funding provides hc1 with capital to address this gap by:
— Powering lab stewardship to ensure patients are tested, diagnosed, and proactively managed to maximize health and longevity.
— Optimizing patient blood management and managing patients with anemia to improve outcomes and reduce costs.
— Eliminating waste in the supply chain and ensuring staffing levels are aligned utilizing advanced analytics, AI, benchmarking, and implanting best practices.
— Achieving profitable growth for health systems through effective lab outreach.
The funding and hc1’s recent acquisition of Accumen strengthen the company’s position as the leader in transforming diagnostic labs into strategic assets for healthcare systems, positively impacting patient care through improved diagnoses and optimized treatment.
Ziegler, a specialty investment bank, advised hc1 on its acquisition of Accumen.
KEY QUOTES:
“Having these esteemed investors join Health Cloud Capital alongside our Accumen acquisition provides a resounding endorsement for hc1’s strategy and team. Beyond capital, A1 Health Ventures and Arsenal Capital Partners bring unique access to industry thought leaders, talent, and health system partners to unlock the value of actionable lab data.”
– hc1 founder and CEO Bradley Bostic
“Ongoing pressures on healthcare delivery operations and financing require providers, payors, and pharma manufacturers to utilize insights from a massive, growing base of patient data. hc1’s solutions support proactive management of longitudinal patient health, rather than reflexive responses to point-in-time care events. Their technology platform is uniquely positioned as the leader in identifying risk signals and insights in diagnostic lab data. As a result, their clients gain insights that improve patient care while enhancing financial results. hc1 ideally aligns with our strategy to leverage data at scale using advanced data science and expert services to drive sustainable improvements in healthcare delivery.”
– A1 Health Ventures Managing Director Jon Phillips
